OBJECTIVE: The Honduran HIV/AIDS Program began to scale up access to HIV therapy in 2002. Up to May 2008, more than 6000 patients received combination antiretroviral therapy (cART). As HIV drug resistance is the major obstacle for effective treatment, the purpose of this study was to assess the prevalence of antiretroviral drug resistance in Honduran HIV-1-infected individuals. METHODS: We collected samples from 138 individuals (97 adults and 41 children) on cART with virological, immunological or clinical signs of treatment failure. HIV-1 pol sequences were obtained using an in-house method. Resistance mutations were identified according to the 2007 International AIDS Society (IAS)-USA list and predicted susceptibility to cART was scored using the ANRS algorithm. RESULTS: Resistance mutations were detected in 112 patients (81%), 74% in adults and 98% in children. Triple-, dual- and single-class drug resistance was documented in 27%, 43% and 11% of the study subjects, respectively. Multiple logistic regression showed that resistance was independently associated with type of treatment failure [virological failure (odds ratio (OR) = 1) vs. immunological failure (OR = 0.11; 95% confidence interval (CI) 0.030-0.43) vs. clinical failure (OR = 0.037; 95% CI 0.0063-0.22)], route of transmission (OR = 42.8; 95% CI 3.73-491), and years on therapy (OR = 1.81; 95% CI 1.11-2.93). CONCLUSION: The prevalence of antiretroviral resistance was high in Honduran HIV-infected patients with signs of treatment failure. A majority of study subjects showed dual- or triple-class resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Virologically defined treatment failure was a strong predictor of resistance, indicating that viral load testing is needed to correctly identify patients with treatment failure attributable to resistance.
OBJECTIVE: The Honduran HIV/AIDS Program began to scale up access to HIV therapy in 2002. Up to May 2008, more than 6000 patients received combination antiretroviral therapy (cART). As HIV drug resistance is the major obstacle for effective treatment, the purpose of this study was to assess the prevalence of antiretroviral drug resistance in Honduran HIV-1-infected individuals. METHODS: We collected samples from 138 individuals (97 adults and 41 children) on cART with virological, immunological or clinical signs of treatment failure. HIV-1 pol sequences were obtained using an in-house method. Resistance mutations were identified according to the 2007 International AIDS Society (IAS)-USA list and predicted susceptibility to cART was scored using the ANRS algorithm. RESULTS: Resistance mutations were detected in 112 patients (81%), 74% in adults and 98% in children. Triple-, dual- and single-class drug resistance was documented in 27%, 43% and 11% of the study subjects, respectively. Multiple logistic regression showed that resistance was independently associated with type of treatment failure [virological failure (odds ratio (OR) = 1) vs. immunological failure (OR = 0.11; 95% confidence interval (CI) 0.030-0.43) vs. clinical failure (OR = 0.037; 95% CI 0.0063-0.22)], route of transmission (OR = 42.8; 95% CI 3.73-491), and years on therapy (OR = 1.81; 95% CI 1.11-2.93). CONCLUSION: The prevalence of antiretroviral resistance was high in Honduran HIV-infectedpatients with signs of treatment failure. A majority of study subjects showed dual- or triple-class resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Virologically defined treatment failure was a strong predictor of resistance, indicating that viral load testing is needed to correctly identify patients with treatment failure attributable to resistance.
Authors: Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Ethan Obie Romero-Severson; Cody Lee Petrie; Edward Ionides; Jan Albert; Thomas Leitner Journal: Int J Epidemiol Date: 2015-07-10 Impact factor: 7.196
Authors: Karidia Diallo; Wendy E Murillo; Ivette Lorenzana de Rivera; Jan Albert; Zhiyong Zhou; John Nkengasong; Guoqing Zhang; Jennifer F Sabatier; Chunfu Yang Journal: Int J Mol Epidemiol Genet Date: 2012-02-28
Authors: Maja M Lunar; Snježana Židovec Lepej; Ana B Abecasis; Janez Tomažič; Ludvik Vidmar; Primož Karner; Tomaž D Vovko; Blaž Pečavar; Polona J Maver; Katja Seme; Mario Poljak Journal: AIDS Res Hum Retroviruses Date: 2012-08-29 Impact factor: 2.205
Authors: Ann M Dennis; Wendy Murillo; Flor de Maria Hernandez; Maria Elena Guardado; Ana Isabel Nieto; Ivette Lorenzana de Rivera; Joseph J Eron; Gabriela Paz-Bailey Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Annika Karlsson; Per Björkman; Göran Bratt; Håkan Ekvall; Magnus Gisslén; Anders Sönnerborg; Mattias Mild; Jan Albert Journal: PLoS One Date: 2012-03-20 Impact factor: 3.240
Authors: Alexandra U Scherrer; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Hansjakob Furrer; Alexandra Calmy; Matthias Cavassini; Luigia Elzi; Pietro L Vernazza; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard Journal: PLoS One Date: 2012-11-26 Impact factor: 3.240